Format

Send to

Choose Destination
Ann Oncol. 2015 May;26(5):992-7. doi: 10.1093/annonc/mdv029. Epub 2015 Jan 26.

Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions.

Author information

1
Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam r.w.f.vanleeuwen@erasmusmc.nl.
2
Department of Clinical Pharmacy, Deventer Hospital, Deventer Department of Pharmacotherapy and Pharmaceutical Care, State University Groningen, Groningen.
3
Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam.
4
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam.
5
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam.
6
Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Abstract

BACKGROUND:

Drug-drug interactions (DDIs) are of major concern in oncology, since cancer patients typically take many concomitant medications. Retrospective studies have been conducted to determine the prevalence of DDIs. However, prospective studies on DDIs needing interventions in cancer patients have not yet been carried out. Therefore, a prospective study was designed to identify DDIs leading to interventions among ambulatory cancer patients receiving anticancer treatment.

PATIENTS AND METHODS:

Patients starting with a new treatment regimen with i.v. or oral anticancer medication were asked to participate. The patients' medication was checked for DDIs by using drug interaction software. An expert team of clinical pharmacologists evaluated the relevance of these identified DDIs. If a DDI was qualified as potentially clinically relevant, an intervention was proposed to the treating (hemato)oncologist. Several variables were studied as determinants for performing an intervention. Descriptive statistics and uni- and multivariate logistic regression analyses were carried out.

RESULTS:

In this study, 302 patients were included. A total of 603 DDIs were identified by the drug interaction software and judged by the expert team. Of all 603 DDIs, 120 DDIs were considered potentially clinically relevant. These 120 DDIs, present in a total of 81 patients, resulted in a clinical intervention already executed by the (hemato)oncologist in 39 patients (13%), while an additional intervention was proposed by a clinical pharmacologist in 42 patients (14%). The number of comorbidities and the number of 'over-the-counter' drugs were identified as determinants.

CONCLUSIONS:

Clinical interventions on DDIs are frequently required among patients starting with anticancer therapy. Structured screening for these potentially clinically relevant DDIs, by (hemato)oncologists in close collaborations with clinical pharmacologists, should take place before the start and during anticancer treatment.

CLINICAL TRIALS NUMBER:

This study was registered at the Dutch Trial Registry under number NTR3760.

KEYWORDS:

cancer; drug–drug interactions; medication review; pharmacodynamics; pharmacokinetics; pharmacology

PMID:
25628444
DOI:
10.1093/annonc/mdv029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center